These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 7680986)

  • 21. Proper sequence of endocrine therapies in advanced breast cancer.
    Rose C
    Acta Oncol; 1996; 35 Suppl 5():44-9. PubMed ID: 9142964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
    Lønning PE
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
    Geisler J; Johannessen DC; Anker G; Lønning PE
    Eur J Cancer; 1996 May; 32A(5):789-92. PubMed ID: 9081355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
    Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
    Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aromatase and other inhibitors in breast and prostatic cancer.
    Brodie AM; Banks PK; Inkster SE; Son C; Koos RD
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1043-8. PubMed ID: 2285580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
    Höffken K; Jonat W; Possinger K; Kölbel M; Kunz T; Wagner H; Becher R; Callies R; Friederich P; Willmanns W
    J Clin Oncol; 1990 May; 8(5):875-80. PubMed ID: 2185341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
    Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
    Friedrichs K; Jänicke F
    Praxis (Bern 1994); 1998 Apr; 87(17):584-8. PubMed ID: 9623325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined inhibitory effect of formestane and herceptin on a subpopulation of CD44+/CD24low breast cancer cells.
    Cavaliere C; Corvigno S; Galgani M; Limite G; Nardone A; Veneziani BM
    Cancer Sci; 2010 Jul; 101(7):1661-9. PubMed ID: 20491779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
    Coombes RC
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):145-8. PubMed ID: 1525056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
    MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
    Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.
    Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Celio L; Bichisao E
    Cancer Treat Rev; 1993 Apr; 19 Suppl B():31-6. PubMed ID: 8481932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formestane for advanced breast cancer in postmenopausal women.
    Drug Ther Bull; 1993 Oct; 31(22):85-7. PubMed ID: 8269826
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
    Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
    Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.
    Coombes RC; Hughes SW; Dowsett M
    Eur J Cancer; 1992; 28A(12):1941-5. PubMed ID: 1419285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
    Michaud LB; Buzdar AU
    Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
    Pérez N; Borja J
    J Int Med Res; 1992 Aug; 20(4):303-12. PubMed ID: 1387368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.